Drugs / TBI1501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03155191 | Jun 2017 → Mar 2035 expected | adult acute lymphoblastic leukemia | Takara Bio Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI1501 | “Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells” NCT03155191 ↗ |
| Known as | CD19-CAR-T cells | “Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells” NCT03155191 ↗ |
| Modality | Cell therapy | “autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR)” NCT03155191 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT03155191 ↗ |
| Target | CD19 | “anti-CD19 chimeric antigen receptor (CAR)” NCT03155191 ↗ |